Xueshuantong Combined Fibrinolytic Treatment Of Acute Cerebral Infarction

Objective:Acute cerebral infarction (acute cerebral infarction ACI), also known as ischemic stroke are in the areas of stroke medicine. Acute cerebral infarction is the most common form of neurological sudden sudden illness, the disability in a high death rate is quite high, seriously affecting people's quality of life. How to timely and effective treatment of acute cerebral infarction, and minimize the death rate and disability rate, is currently a serious problem. In recent years, Integrative prevention and treatment of acute cerebral infarction made a lot of good. This issue combined with Xueshuantong plasminogen in acute cerebral infarction, by observing its rate of neurological deficit score, ADL score (ADL), Chinese medicine symptom points, hemorheology, PT (s), FIB's impact, and the overall clinical efficacy were compared to evaluate the joint plasminogen Xueshuantong clinical treatment of acute cerebral infarction, and its mechanism, the Chinese and Western theoretical basis for treatment of acute cerebral infarction.Method:1. Clinical Data All cases from December 2008-2009 Chinese medicine hospital in Hubei Province, Department of Neurology in November and the Wuhan University People's Hospital of hospitalized patients were randomly divided into treatment group and control group, treatment group 60 cases,60 cases were treated. Combined treatment group received fibrinolytic therapy Xueshuantong the control group received fibrinolytic therapy.2. Drug Usage Both groups received routine treatment, includ-eing the regulation of blood pressure, blood sugar, anti-infection and treatment when necessary, reducing the intracranial pressure. Treatment group 500mg injection Xueshuantong adding 0.9% sodium chloride injection 250ml or 250ml of 5% glucose injection given intravenously once a day, for continuous 14 days. At the same time injecting with plasminogen 200U (first dose of 100U) in 0.9% sodium chloride injection 250ml or 250ml of 5% glucose injection given intravenously once a day, for continuous 10 days. The control group injected with plasminogen 200U (first dose of 100U) in 0.9% sodium chloride injection 250ml or 250ml of 5% glucose injection given intravenously once a day, for continuous 10 days.3.Observation The total clinical efficacy were observed, neurological deficit score value, stroke syndromes score, activities of daily living (ADL) score, blood flow changes check, PT (S), FIB, and did statistical analysis.4. Safety Observation General situation:body temperature, heart rate, respiration, blood pressure; treatment of newly diagnosed before and after the first day and 14 days after treatment all do a laboratory test to blood, urine, stool, liver and kidney function, ECG, CT or Cranial MRI as a safety indicator, monitoring of adverse reactions at any time.Results:1. Determine the overall clinical efficacy Treatment of the basic recovery after 14 days treatment group number 5, the number of 32 cases markedly effective, effective number of 19 cases, total effective rate was 93.3%; in control group 3 patients recovered, the number of 27 cases markedly effective, effective number more than 20 cases, The total effective rate was 83.3%. The Ridit test between two groups were significantly different (P<0.05). Description Xueshuantong United plasminogen than plasmin treatment of acute cerebral infarction significantly.2. Clinical efficacy of neurologic impairment Comparative Analysis Treatment group after treatment, neurological deficit score 8.12±7.48, treatment group, neurological deficit score 12.39±8.67, statistically compared the treatment group and control group P <0.05. The results suggest that plasmin promotes thrombosis through the joint in patients with acute cerebral infarction recovery of neurological function.3. On the stroke of disease syndromes Treatment group 14 days after treatment clinical cure in 6 cases,33 cases markedly effective in 15 cases, the total effective rate was 90.0%; in control group 3 cases were cured,20 cases markedly effective in 25 cases, total effective rate was 80.0%. The Ridit test between two groups were significantly different (P<0.05). Description Xueshuantong combined treatment of acute cerebral infarction plasminogen stroke symptoms and signs improved significantly better than the control group.4. Activities of daily living(ADL) examination Before and after treatment were compared by t test, P<0.05, ADL score before and after treatment control group was statistically significant P <0.05, treatment group, ADL score before and after treatment was statistically significant P<0.05, after treatment between the two groups was statistically significant the treatment group is superior. This part of the results suggest that thrombosis combined fibrinolytic therapy of acute cerebral infarction through increased ADL score, and promote the activities of daily living in patients with acute cerebral infarction recovery.5. On hemorheology in patients before treatment hemorheology was no difference (P>0.05); before and after treatment, the treatment group before and after treatment with high shear whole blood viscosity, low shear whole blood viscosity, statistically significant differences in plasma viscosity; the control group before and after treatment showed no statistical significance; treatment group and control group after treatment between the two groups, the treatment group improved high shear blood viscosity was significantly higher than the control group.6. PT (s), FIB inspection Before treatment, two groups were PT (s), FIB test was not significant (P> 0.05); treatment group and control group before and after the FIB treatment was significantly (P<0.01); the treatment group than in the control group FIB FIB has statistical significance P<0.05. Treatment group and control group before and after treatment PT(s) not statistically significant.7. Comparative analysis of the security Treatment group and control group in general, the normal period of clinical observation, two groups of blood, liver and kidney function, stool, stool occult blood, prothrombin time, ECG, CT or MRI had no abnormal condition, without adverse reaction effects and toxicity.Conclusion:Through this clinical study demonstrated thrombosis combined fibrinolytic treatment of acute cerebral infarction through the timely restoration of blood supply to ischemic areas, improving the brain microcirculation, promote the establishment of collateral circulation to the surrounding penumbra of cerebral function, and then stop the progress of cerebral infarction to enhance acute cerebral infarction, and better than the use of fibrinolytic therapy alone. This study shows that in the non-thrombolytic therapy approach, using Chinese and western medicine has obvious advantages.